Information
IM156 IM156 (HL156A), a metformin derivative, is a potent activator of AMPK that increases AMPK phosphorylation. IM156 blocks oxidative phosphorylation (OXPHOS) through the inhibition of complex I and increases apoptosis . IM156 ameliorates various types of fibrosis and inhibits tumors.
Targets
AMPK ; OXPHOS
In vitro
IM156 (HL156A) treatment of RPMCs inhibits HG-induced myofibroblast transdifferentiation and markers of epithelial-mesenchymal transition (EMT). Moreover, IM156 (HL156A) ameliorates HG-induced transforming growth factor-β1, Smad3, Snail, and fibronectin expression in the RPMCs via AMPK upregulation. IM156 treatment decreases complex I-dependent NADH oxidation in a significant, dose-dependent manner.
In vivo
In vivo treatment of IM156 exacerbated the memory differentiation of virus-specific CD8+ T cells results in an increase in short-lived effector cells but decrease in memory precursor effector cells. Thus, IM156 treatment impaires the function of virus-specific memory CD8+ T cells, indicating that excessive AMPK activation weakens memory T cell differentiation, thereby suppressing recall immune responses.
Cell Research(from reference)
Cell lines：Rat peritoneal mesothelial cells (RPMCs)
Concentrations：10 μM, 30 μM, 50 μM
Incubation Time：24 h
